Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

NCT07057310 on ClinicalTrials.gov · last registry update 2026-07-20

A small phase 4 — 30 participants, against a typical 75. Due to report 31 December 2026, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Physical Function Measure: Short Physical Performance Battery (SPPB) score. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: ENROLLING_BY_INVITATION
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Mayo Clinic
Sponsor type: Other
Enrollment: 30
Started: 2025-05-01
Primary completion: 2026-12-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Physical Function Measure: Short Physical Performance Battery (SPPB) score.

Conditions studied

Obesity · Menopause

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.